Norihisa Ishiwata

This inventor holds 13 USPTO granted patents and 5 published patent applications, plus 2 CIPO patents and 1 EPO patent. Top assignees: Nissan Chemical Industries Limited, Reprocell, Inc.. Active years: 2008-2016.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Norihisa Ishiwata. Retrieved from https://idiyas.com/inventor/norihisa-ishiwata

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 13 (Patent Applications = 5)

% Patents Active = 23.1

CIPO Patents = 2

EPO Patents = 1 (Patent Applications = 4)

Average Co-Inventor Count = 5.9

ph-index = 4

Forward Citations = 49(Granted Patents)

Location History:

Saitama, JP (2010 - 2011)
Minami-saitama-gun, JP (2008 - 2016)

Company Filing History:

13 out of 1,235

Nissan Chemical Industries Limited

where one patent can have more than one assignee

Years Active: 2008-2016

Loading Chart...

13 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9527828 - Method for expanding hematopoietic stem cells using heterocyclic compound (2016-12-27),

2. 9115341 - Method for expanding hematopoietic stem cells using heterocyclic compound (2015-08-25),

3. 8552031 - 3-ethylidenehydrazino substituted heterocyclic compounds as thrombopoietin receptor activators (2013-10-08),

4. 8318796 - Heterocyclic compounds and thrombopoietin receptor activators (2012-11-27),

5. 8134013 - Amide compound and thrombopoietin receptor activator (2012-03-13),

6. 8093251 - Nitrogen-containing heterocyclic compounds and thrombopoietin receptor activators (2012-01-10),

7. 8053453 - Pyrazolone compounds and thrombopoietin receptor activator (2011-11-08),

8. 8026368 - Hydrazide compounds and thrombopoietin receptor activators (2011-09-27),

9. 7968542 - Thiophene compounds and thrombopoietin receptor activators (2011-06-28),

10. 7960425 - Pyrazole compounds and thrombopoietin receptor activators (2011-06-14),

11. 7851503 - Thrombopoetin receptor activator and process for producing the same (2010-12-14),

12. 7576115 - Heterocyclic compounds and thrombopoietin receptor activators (2009-08-18),

13. 7351841 - Heterocyclic compounds and thrombopoietin receptor activators (2008-04-01),

Title: The Innovative Contributions of Norihisa Ishiwata

Introduction

Norihisa Ishiwata, an accomplished inventor from Minamisaitama-gun, Japan, has made significant contributions in the field of hematopoietic stem cell research. With a portfolio of 13 patents to his name, Ishiwata is recognized for his innovative methods that aim to improve treatments for various hematopoietic disorders.

Latest Patents

Among his latest inventions is a method for expanding hematopoietic stem cells using heterocyclic compounds. This invention provides an expansion agent for hematopoietic stem cells, which enhances gene transfer efficiency into these cells, paving the way for effective gene therapy options. The method describes culturing hematopoietic stem cells and/or progenitor cells ex vivo in the presence of specific compounds, which are chemically defined within his patent documentation.

Moreover, Ishiwata has focused on expanding CD34 cells ex vivo in a biologically safe and cost-effective manner. His method seeks to utilize low molecular weight compounds that can efficiently increase the quantity of CD34 cells, which are essential for the treatment of hematopoietic disorders stemming from dysfunctional stem cells.

Career Highlights

Ishiwata's career has been marked by impactful roles at reputable companies. He has contributed significantly while working at Nissan Chemical Industries Limited and Reprocell, Inc., where he further refined his expertise in stem cell research and innovative therapeutic solutions.

Collaborations

Throughout his career, Norihisa Ishiwata has collaborated with notable professionals in his field, including coworkers Katsuaki Miyaji and Yutaka Hirokawa. These collaborations have likely enriched his research and expanded the scope of his innovations in hematopoietic stem cell applications.

Conclusion

Norihisa Ishiwata exemplifies the spirit of innovation with his work centered on hematopoietic stem cells. Through his patents, he has not only contributed to scientific understanding but also provided tangible methods that can improve treatments for blood-related disorders. His ongoing dedication to research and collaboration continues to hold promise for future advancements in the field.

Profile summary based on public USPTO records.